Articles from Lynch Regenerative Medicine, LLC

Lynch Regenerative Medicine, LLC., (LRM) announced today that it has acquired exclusive rights to REGRANEX® gel and recombinant purified platelet-derived growth factor (PDGF) from Smith & Nephew, Inc., for use in skin rejuvenation and regeneration as well as other soft tissue wound healing and tissue regeneration applications. PDGF is the first and only pure recombinant growth factor to have received approval from the U.S. Food and Drug Administration (FDA) for the treatment of wounds in the lower extremities of diabetic patients. The terms of the transaction were not disclosed.

Tod Reed will join Lynch Regenerative Medicine, LLC (LRM) as a Senior Strategic Advisor. Reed recently retired as the Senior Vice President, U.S. Sales and Sales Training, at Allergan Aesthetics, an Abbvie company.

Lynch Regenerative Medicine, LLC (LRM) has completed its Series A financing to develop and commercialize innovative skin rejuvenation and regeneration solutions based on the only tissue growth factor that has been approved by the FDA and other international regulator bodies to be safe and effective in human tissue regeneration and wound healing, pure platelet-derived growth factor (PDGF). LRM’s Series A financing round was led by Champion VC, a family office investor managing the assets of members of the Frist family of Nashville, Tennessee, and Dr. Samuel Lynch, founder and CEO of LRM.